Cannabis and CBD Stocks are Old News, The Next Hot Peripheral Sector is Here!
April 16 2020 - 8:00AM
InvestorsHub NewsWire
Cannabis and CBD Stocks are Old
News, The Next Hot Peripheral Sector is Here!
New York, NY -- April 16, 2020 --
InvestorsHub NewsWire -- via Traders News
Source -- Traders News Source, a leading
independent equity research and corporate access firm focused on
small cap growth companies’ issues their latest research “The Next
Hot Sector”
In February,
BioElectronics Corporation (OTC:
BIEL) obtained a new 510(k) clearance from the U.S.
Food and Drug Administration (FDA). This new, over-the-counter
marketing clearance was granted for the drug-free ActiPatch®
medical device, for adjunctive treatment of musculoskeletal pain.
The ActiPatch was already FDA-cleared for over-the-counter
treatment of pain from knee osteoarthritis and plantar fasciitis
(heel pain) in 2017.
Arrayit Corporation
(OTC:
ARYC) works in the biotechnology, pharmaceutical,
clinical and healthcare sectors through the discovery, development
and manufacture of proprietary life science and personalized
medicine products. Last August, the company was approved by a
leading Medicare Administrative Contractor (MAC) on behalf of the
Centers for Medicare and Medicaid Services (CMS) as a new allergy
testing services healthcare provider for Medicare Part
B.
Ever wish you were aware of a hot
new sector before it experiences explosive growth? Hot new sector
in its infancy gaining traction now READ
MORE
Copy and paste to browser may be
required https://www.industrynews.tips/
Connectyx Technologies
Holdings Group, Inc. (OTC:
CTYX) recently issued a shareholder update. The
highlights from the update included: SunMed Advisors, LLC has
recently acquired majority control of CTYX through the purchase of
Series A Preferred stock from the two principal holders of CTYX.
Jon Pevzner, former President and Director has resigned, and Paul
M. Michaels was appointed Interim CEO and Director. Dr. Barry A.
Ginsberg and Brandon Michaels join Mr. Michaels on the Board. CTYX
will continue to update shareholders on a new business plan through
news releases, website updates and OTCMarkets filings as the
company moves forward.
Innovation Pharmaceuticals
Inc. (OTCQB:
IPIX) has developed Brilacidin, a versatile compound
with broad therapeutic potential, is in a new chemical class called
defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse
for the prevention of Severe Oral Mucositis (SOM) in patients with
Head and Neck Cancer, met its primary and secondary endpoints,
including reducing the incidence of SOM. The company announced on
March 9th that. Brilacidin has been submitted for
testing against SARS-CoV-2, the specific coronavirus responsible
for COVID-19. Brilacidin is immediately being placed into queue
and the Company anticipates confirmation of the testing schedule as
well as procedures for the studies later this
week.
Ever wish you were aware of a hot
new sector before it experiences explosive growth? Hot new sector
in its infancy gaining traction now READ
MORE
Copy and paste to browser may be
required – https://www.industrynews.tips/
Disclosure
Traders News Source LLC (TNS)
produces regular sponsored and non-sponsored reports, articles,
stock market blogs, and popular investment newsletters covering
small and micro-cap equity markets. TNS has two distinct and
independent departments. One department produces non-sponsored
analyst certified content generally in the form of press releases,
articles and reports covering equities listed on NYSE, NASDAQ and
OTC exchanges. The other produces sponsored content (in most cases
not reviewed by a registered analyst), which typically consists of
compensated investment newsletters, articles and reports covering
listed stocks and micro-caps. Such sponsored content is outside the
scope of procedures detailed below.
PRESS RELEASE
PROCEDURES
The sponsored and non-sponsored
content contained herein has been prepared by a writer (the
"Author") and is fact checked and reviewed by a third-party
research service company (the "Reviewer") represented by a
chartered financial analyst, for further information on analyst
credentials, please email editor@tradersnewssource.com.
TNS LLC provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written, and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author per
the procedures outlined by TNS. TNS is not entitled to veto or
interfere in the application of such procedures by the third-party
research service company to the articles, documents, or reports.
Unless otherwise noted, any content outside of this document has no
association with the Author or the Reviewer in any
way.
NO WARRANTY
TNS, the Author, and the Reviewer
are not responsible for any error which may be occasioned at the
time of printing of this document or any error, mistake, or
shortcoming. No liability is accepted whatsoever for any direct,
indirect, or consequential loss arising from the use of this
document. TNS, the Author, and the Reviewer expressly disclaim any
fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Additionally, TNS, the Author, and
the Reviewer do not (1) guarantee the accuracy, timeliness,
completeness, or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as
an offering, recommendation, or a solicitation of an offer to buy
or sell the securities mentioned or discussed and is to be used for
informational purposes only. Please read all associated disclosures
and disclaimers in full before investing. Neither TNS nor any party
affiliated with us is a registered investment adviser or
broker-dealer with any agency or in any jurisdiction whatsoever. To
read our report(s), disclosures, or for more information, visit
http://www.tradersnewssource.com.
For any questions, inquiries, or
comments reach out to us directly. If you're a company we are
covering and wish to no longer be featured on our coverage list,
contact us via email at: editor@tradersnewssource.com
CFA® and Chartered Financial
Analyst® are registered trademarks owned by CFA
Institute.
CONTACT: editor@tradersnewssource.com
SOURCE: Traders News
Source
Arrayit (CE) (USOTC:ARYC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Arrayit (CE) (USOTC:ARYC)
Historical Stock Chart
From Oct 2023 to Oct 2024